Avtor/Urednik		Šebeštjen, Miran; Keber, Irena; Žegura, Branka; Simčič, Saša; Božič, Mojca; Migaud-Fressart, Martine; Stegnar, Mojca
Naslov		Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors
Tip		članek
Vir		Thromb Haemost
Vol. in št.		Letnik 92
Leto izdaje		2004
Obseg		str. 1129-35
Jezik		eng
Abstrakt		The effects of cerivastatin and fenofibrate on proteins involved in haemostasis and on markers of inflammation were investigated in otherwise healthy middle-aged males with combined hyperlipidemia. Besides classical risk factors, other so-called novel risk factors for coronary artery disease are seen to be playing an increasingly important role in the development and progression of atherosclerosis. Thirty-eight males, aged 49 ± 5 years were randomised to 12 weeks treatment either with cerivastatin at a daily dose of 0.2 mg to 0.4 mg to achieve the LDL cholesterol goal of < 3.0 mM, or with fenofibrate 250 mg daily. Fasting serum lipids, homocysteine, total and free tissue factor pathway inhibitor (TFPI), plasminogen activator inhibitor (PAI-1) and tissue plasminogen activator (t-PA) antigen and activity, C-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor-a (TNF-alpha) were measured. (Abstract truncated at 2000 characters)
Deskriptorji		HYPERLIPIDEMIA CORONARY DISEASE PROCETOFEN ANTILIPEMIC AGENTS LIPOPROTEINS, LDL CHOLESTEROL MIDDLE AGE RISK FACTORS BLOOD PRESSURE HOMOCYSTEINE PLASMINOGEN ACTIVATOR INHIBITOR 1 ALTEPLASE C-REACTIVE PROTEIN INTERLEUKIN-6 TUMOR NECROSIS FACTOR CHOLESTEROL TRIGLYCERIDES CREATININE LIPOPROTEINS, HDL CHOLESTEROL